Clinical Trials
48 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
National Cancer Institute (NCI)
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
National Institutes of Health Clinical Center (CC)
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
National Institutes of Health Clinical Center (CC)
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
National Institutes of Health Clinical Center (CC)
Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy
National Cancer Institute (NCI)
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Sunitinib in Sarcomas of the Central Nervous System
National Institutes of Health Clinical Center (CC)
ASSURE
National Cancer Institute (NCI)
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
National Institutes of Health Clinical Center (CC)
Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer
National Cancer Institute (NCI)
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
National Cancer Institute (NCI)
Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
National Cancer Institute (NCI)
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
National Institutes of Health Clinical Center (CC)
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
National Cancer Institute (NCI)
Sunitinib to Treat Recurrent Brain Cancer
National Institutes of Health Clinical Center (CC)
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
National Cancer Institute (NCI)
Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
National Cancer Institute (NCI)
Sunitinib in Treating Patients With Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma
National Cancer Institute (NCI)
Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
National Cancer Institute (NCI)
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
National Cancer Institute (NCI)
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors
National Cancer Institute (NCI)
Sunitinib in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
National Cancer Institute (NCI)
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
National Cancer Institute (NCI)
Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer
National Cancer Institute (NCI)
Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer
National Cancer Institute (NCI)
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
National Cancer Institute (NCI)
Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
National Cancer Institute (NCI)
Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
National Cancer Institute (NCI)
Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
National Cancer Institute (NCI)